Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
2019
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are aggressive hematologic malignancies that are currently still treated by high-dose chemotherapy possibly followed by hematopoietic stem cell transplantation.[1][1] Despite important progress in deciphering the
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
14
References
12
Citations
NaN
KQI